Overview

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.

Status:
Terminated
Trial end date:
2017-10-23
Target enrollment:
Participant gender:
Summary
Myelofibrosis patients with high molecular risk mutations have an intrinsically aggressive disease with increased risk of leukemic transformation and reduced overall survival. As there are no therapies currently established in the subset of high molecular risk patients with early myelofibrosis, the study aimed to evaluate ruxolitinib in this patient population.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals